Caplyta (lumateperone) has scored a label extension into the depression setting, underscoring the belief Johnson & Johnson (J ...

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being ...

Cencora is set to invest $1bn by 2030 to expand its US pharmaceutical distribution network, adding resilience and capacity.

The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with ...

Leukogene Therapeutics has received orphan drug designation from the US FDA for M2T-CD33 (LTI-214), its immunotherapy candidate targeting AML.

The guidance change marks the latest adjustment Novo has made to its 2025 outlook as the company battles a changing market.

Avant Technologies and SGAustria have announced a joint venture (JV) and licence agreement to advance a therapy for diabetes ...

ADCs remain à la mode in the oncology sector, with Merck & Co (MSD) tying up another deal to advance its pipeline in the ...

Here are three important regulatory changes affecting parenteral packaging that pharmaceutical companies need to be aware of ...

Both companies have upped their offers for Metsera amid a bidding war, but Novo Nordisk comes armed with an extra $1.9bn.

The path to approval for uniQure’s gene therapy candidate for Huntington’s disease is in doubt as the US Food and Drug ...

Ensuring fair drug pricing was a key promise of Sri Lanka’s government’s election manifesto, and that promise is finally ...